gsk

GSK plc commences share buyback programme

GSK plc ("GSK") today announces the commencement of its share buyback programme (the “Programme”), as announced in its 2024 full year results announcement published on 5 February 2025 (the “FY24 ...
gsk

GSK completes acquisition of RAPT Therapeutics

GSK plc (LSE/NYSE: GSK) today announced the completion of its previously announced acquisition of RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to ...
gsk

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026 GSK plc (LSE/NYSE: GSK) today announced positive results ...
gsk

GSK’s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis

Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients Differentiated mechanism of action addresses key manifestations of myelofibrosis, namely anaemia, ...
gsk

ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1

Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA Foundation (FSG) showed DTG/3TC demonstrated non-inferior efficacy compared to BIC/FTC/TAF as ...
gsk

Analyst consensus

The consensus has been collated from estimates submitted by analysts to GSK using a standard template. The information is provided purely for convenience to users of our website, for information ...
gsk

GSK enters exclusive license agreement with Hansoh for HS-20093

Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates, following earlier agreement for Hansoh’s HS-20089 focused on gynaecologic cancers HS-20093 has shown ...
gsk

Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations

SWIFT-1 and SWIFT-2 phase III data show depemokimab delivered a statistically significant and clinically meaningful reduction in exacerbations over 52 weeks versus placebo plus standard of care, in ...
gsk

GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler

Data confirm therapeutic equivalence and comparable safety profile for Ventolin (salbutamol) containing innovative low carbon propellant Approximately 300 million salbutamol MDIs are sold globally ...
gsk

GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

GSK plc (LSE/NYSE: GSK) and Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, ...
gsk

GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK

GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot ...
gsk

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts ...

Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...